China's drug regulator approved Zhejiang Xianju Pharmaceutical's (SHE:002332) registration of its betahistine mesylate tablets, according to a Saturday filing with the Shenzhen Stock Exchange.
The tablets are indicated for vertigo associated with Meniere's disease, the filing said.